NCT06138041View on ClinicalTrials.gov

Intravenous Lidocaine Infusion Reduce Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy

NANot yet recruitingINTERVENTIONAL
Enrollment

770

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

August 30, 2025

Conditions
Postoperative PneumoniaPostoperative Pulmonary AtelectasisPostoperative Pulmonary Edema
Interventions
DRUG

intravenous lidocaine infusion

Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.

DRUG

Saline

Same volume of normal saline in bolus and continuous infusion as lidocaine group.

All Listed Sponsors
lead

Sichuan Cancer Hospital and Research Institute

OTHER

NCT06138041 - Intravenous Lidocaine Infusion Reduce Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy | Biotech Hunter | Biotech Hunter